References
[1]. Taher AT, Cappellini MD, Musallam KM. Development of a
thalassemia-related thrombosis risk scoring system . Am J Hematol2019; 94(8):E207-E209.
[2]. Barnett R. Thalassaemia . Lancet 2019;
394(10204):1135.
[3]. Ren Q, Zhou YL, Wang L, et al. Clinical trial on the
effects of thalidomide on hemoglobin synthesis in patients with moderate
thalassemia intermedia . Ann Hematol 2018; 97(10):1933-1939.
[4]. Shah S, Sheth R, Shah K, et al. Safety and
effectiveness of thalidomide and hydroxyurea combination in
beta-thalassaemia intermedia and major: a retrospective pilot study .Br J Haematol 2020; 188(3):e18-e21.
[5]. Musto P, Falcone A, Sanpaolo G, et al. Thalidomide
abolishes transfusion-dependence in selected patients with
myelodysplastic syndromes . Haematologica 2002; 87(8):884-886.
[6]. Aerbajinai W, Zhu J, Gao Z, et al. Thalidomide induces
gamma-globin gene expression through increased reactive oxygen
species-mediated p38 MAPK signaling and histone H4 acetylation in adult
erythropoiesis . Blood 2007; 110(8):2864-2871.
[7]. Chen J, Zhu W, Cai N, et al. Thalidomide induces
haematologic responses in patients with beta-thalassaemia . Eur J
Haematol 2017; 99(5):437-441.
[8]. Yassin AK. Promising Response to Thalidomide in
Symptomatic beta-Thalassemia . Indian J Hematol Blood Transfus2020; 36(2):337-341.
[9]. Masera N, Tavecchia L, Capra M, et al. Optimal response
to thalidomide in a patient with thalassaemia major resistant to
conventional therapy . Blood Transfus 2010; 8(1):63-65.
[10]. Aguilar-Lopez LB, Delgado-Lamas JL, Rubio-Jurado B, et al.Thalidomide therapy in a patient with thalassemia major .Blood Cells Mol Dis 2008; 41(1):136-137.
[11]. Fozza C, Pardini S, Giannico DB, et al. Dramatic
erythroid response to low-dose thalidomide in two patients with
transfusion independent thalassemia and severe post-transfusional
alloimmune hemolysis . Am J Hematol 2015; 90(7):E141.
[12]. Kalra M, Khanna VK, Trehan A, et al. Thalidomide in
Transfusion Dependent Thalassemia: Hope or Hype . J Pediatr
Hematol Oncol 2017; 39(6):485.
[13]. Li Y, Ren Q, Zhou Y, et al. Thalidomide has a
significant effect in patients with thalassemia intermedia .Hematology 2018; 23(1):50-54.
[14]. Nag A, Radhakrishnan VS, Kumar J, et al. Thalidomide
in Patients with Transfusion-Dependent E-Beta Thalassemia Refractory to
Hydroxyurea: A Single-Center Experience . Indian J Hematol Blood
Transfus 2020; 36(2):399-402.
[15]. Yang K, Wu Y, Zhou Y, et al. Thalidomide for Patients
with beta-Thalassemia: A Multicenter Experience . Mediterr J
Hematol Infect Dis 2020; 12(1):e2020021.
[16]. Yang K, Wu Y, Ma Y, et al. The association of HBG2,
BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese
beta-thalassemia patients . Blood Cells Mol Dis 2020; 84:102442.
[17]. Gunaseelan S, Prakash A. Thalidomide-induced Stroke in
a Child With Thalassemia Major . J Pediatr Hematol Oncol 2017;
39(8):e519-e520.